


V-0219

Cat. No.:	HY-143312	
CAS No.:	878453-71-5	
Molecular Formula:	C ₂₀ H ₂₅ F ₃ N ₄ O ₂	
Molecular Weight:	410.43	
Target:	GLP Receptor	
Pathway:	GPCR/G Protein	
Storage:	Pure form	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (243.65 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.4365 mL	12.1823 mL	24.3647 mL
	5 mM		0.4873 mL	2.4365 mL	4.8729 mL
	10 mM		0.2436 mL	1.2182 mL	2.4365 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.07 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.07 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.07 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research^[1].

IC₅₀ & Target

GLP-1R^[1]

REFERENCES

[1]. Decara JM, et al. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabetes". J Med Chem. 2022 Apr 14;65(7):5449-5461.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA